Skip to main content
. Author manuscript; available in PMC: 2010 May 18.
Published in final edited form as: Vaccine. 2009 Apr 3;27(23):3045–3052. doi: 10.1016/j.vaccine.2009.03.026

Figure 3. BAL eosinophils and neutrophils in mice treated with TLR agonist during RSV challenge or during primary infection.

Figure 3

BALB/c mice were immunized with FI-RSV and treated with TLR agonists either during immunization or during RSV challenge (panel A) and mice of different strains were treated with TLR agonists during primary RSV infection (panel B and C) as detailed in Figure 1. Seven days after RSV infection, BAL was performed, and differential cell counts of the BAL cell pellets were made. The data are represented as the percentage of eosinophils (panels A and B) and neutrophils (panel C) for n=5-6 mice per group.